Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsJeffrey Schlom, Scott Abrams
Life of this patent
Estimating the term…
Abstract
Mutant ras oncogene peptides may induce specific anti-ras cellular immune responses in vaccinated patients. Moreover, a human CD8+ CTL epitope(s) reflecting a specific point mutation in the K-ras oncogene at codon 12 was identified. The mutant ras peptide has implications for both active and passive immunotherapies in selected carcinoma patients. A nested 10-mer peptide was identified [i.e., ras5-14(Asp12)], which was shown to bind to HLA-A2 and display specific functional capacity for expansion of the in-vivo-primed CD8+ CTL precursors.
Claims11
A mutant ras peptide consisting of Tyr Leu Val Val Val Gly Ala Asp Gly Val (SEQ ID NO:
- 11).
A mutant ras peptide-carrier molecule conjugate comprising the mutant ras peptide consisting of Tyr Leu Val Val Val Gly Ala Asp Gly Val (SEQ ID NO:
- 11) and a carrier molecule, wherein said carrier molecule enhances the immunogenicity of the peptide.
A mutant ras peptide-carrier molecule conjugate comprising the mutant ras peptide consisting of Tyr Leu Val Val Val Gly Ala Asp Gly Val (SEQ ID NO:
- 11) and a carrier molecule, wherein said carrier molecule enhances the immunogenicity of the peptide and wherein the carrier molecule is selected from the group consisting of influenza peptide, tetanus toxoid-CD4 epitope, Pseudomonas exotoxin A, and poly-L-lysine.
A mutant ras peptide-carrier molecule conjugate comprising the mutant ras peptide consisting of Tyr Leu Val Val Val Gly Ala Asp Gly Val (SEQ ID NO:
- 11) and a carrier molecule, wherein said carrier molecule enhances the immunogenicity of the peptide and wherein the carrier molecule is tetanus toxoid.
Dependencies are inferred from the claim text.